SCHEMBL23239752

SCHEMBL23239752

COC(=O)[C@H]1CN(c2c(OC)cc(Cl)c(Cl)c2Cl)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.52
NR1H3 Q13133 2/20 0.52
SUV39H2 Q9H5I1 3/20 0.40
PDE4B Q07343 2/20 0.39
ALDH1A1 P00352 1/20 0.38
PTPN1 P18031 1/20 0.37
ALK Q9UM73 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
IMPDH2 P12268 3/20 0.35
CCR1 P32246 2/20 0.35
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23216745 0.91 NR1H2 (0.42) NR1H2NR1H3SUV39H2ALDH1A1ALK
SCHEMBL29886232 0.91 NR1H2 (0.42) NR1H2NR1H3SUV39H2ALDH1A1ALK
SCHEMBL29768486 0.91 NR1H2 (0.42) NR1H2NR1H3SUV39H2ALDH1A1ALK
SCHEMBL29768375 0.90 NR1H2 (0.41) NR1H2NR1H3SUV39H2PDE4BALDH1A1
SCHEMBL23239747 0.90 NR1H2 (0.41) NR1H2NR1H3SUV39H2PDE4BALDH1A1
SCHEMBL23239712 0.88 NR1H2 (0.52) NR1H2NR1H3SUV39H2PDE4BALDH1A1
SCHEMBL29886243 0.78 NR1H2 (0.42) NR1H2NR1H3SUV39H2PDE4BALDH1A1
SCHEMBL23216453 0.78 NR1H2 (0.42) NR1H2NR1H3SUV39H2PDE4BALDH1A1
SCHEMBL29768376 0.78 NR1H2 (0.42) NR1H2NR1H3SUV39H2PDE4BALDH1A1
SCHEMBL30172596 0.78 NR1H2 (0.66) NR1H2NR1H3SUV39H2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230026611-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-01-26 US disclosed
US-20230026611-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-01-26 US disclosed
EP-4041407-A1 ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
WO-2021071802-A1 ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026611-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNA3, KCNH2, KCNJ2 NR1H2 2007/4885NR1H3 2286/4885SUV39H2 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.